Literature DB >> 31816178

High blood pressure in dementia: How low can we go?

Yuda Turana1, Jeslyn Tengkawan1, Yook-Chin Chia2,3, Boon Wee Teo4,5, Jinho Shin6, Guru Prasad Sogunuru7,8, Arieska Ann Soenarta9, Huynh Van Minh10, Peera Buranakitjaroen11, Chen-Huan Chen12, Jennifer Nailes13, Satoshi Hoshide14, Sungha Park15, Saulat Siddique16, Jorge Sison17, Apichard Sukonthasarn18, Jam Chin Tay19, Tzung-Dau Wang20, Narsingh Verma21, Yu-Qing Zhang22, Ji-Guang Wang23, Kazuomi Kario14.   

Abstract

Hypertension is an important public health concern. The prevalence keeps increasing, and it is a risk factor for several adverse health outcomes including a decline in cognitive function. Recent data also show that the prevalence of hypertension and age-related dementia is rising in Asian countries, including in the oldest old group. This study aims to discuss possible treatments for high blood pressure in the elderly and propose an optimal target for BP relative to cognitive outcomes. This review discusses several studies on related blood pressure treatments that remain controversial and the consequences if the treatment target is too low or aggressive. Longitudinal, cross-sectional, and RCT studies were included in this review. An optimum systolic blood pressure of 120-130 mm Hg is recommended, especially in nondiabetic hypertensive patients with significant risk factors. In the oldest old group of patients, hypertension might have a protective effect. The use of calcium channel blockers (CCB) and angiotensin receptor blocker (ARB) is independently associated with a decreased risk of dementia in older people. However, personalized care for patients with hypertension, especially for patients who are frail or very old, is encouraged.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Asia; cognitive dysfunction; dementia; hypertension; oldest old

Mesh:

Substances:

Year:  2019        PMID: 31816178      PMCID: PMC8030000          DOI: 10.1111/jch.13752

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  46 in total

Review 1.  Blood pressure lowering in PROGRESS (Perindopril Protection Against Recurrent Stroke Study) and white matter hyperintensities: should this progress matter to patients?

Authors:  Ernesto L Schiffrin
Journal:  Circulation       Date:  2005-09-13       Impact factor: 29.690

2.  Change in blood pressure and incident dementia: a 32-year prospective study.

Authors:  Robert Stewart; Qian-Li Xue; Kamal Masaki; Helen Petrovitch; G Webster Ross; Lon R White; Lenore J Launer
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

3.  Vascular risk factors and dementia in the general population aged >85 years: prospective population-based study.

Authors:  Sari Rastas; Tuula Pirttilä; Kimmo Mattila; Auli Verkkoniemi; Kati Juva; Leena Niinistö; Esko Länsimies; Raimo Sulkava
Journal:  Neurobiol Aging       Date:  2008-04-01       Impact factor: 4.673

4.  Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study.

Authors:  Ophélia Godin; Christophe Tzourio; Pauline Maillard; Bernard Mazoyer; Carole Dufouil
Journal:  Circulation       Date:  2011-01-10       Impact factor: 29.690

5.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.

Authors:  Françoise Forette; Marie-Laure Seux; Jan A Staessen; Lutgarde Thijs; Marija-Ruta Babarskiene; Speranta Babeanu; Alfredo Bossini; Robert Fagard; Blas Gil-Extremera; Tovio Laks; Zhanna Kobalava; Cinzia Sarti; Jaakko Tuomilehto; Hannu Vanhanen; John Webster; Yair Yodfat; Willem H Birkenhäger
Journal:  Arch Intern Med       Date:  2002-10-14

6.  A U-shaped Association Between Blood Pressure and Cognitive Impairment in Chinese Elderly.

Authors:  Yue-Bin Lv; Peng-Fei Zhu; Zhao-Xue Yin; Virginia Byers Kraus; Diane Threapleton; Choy-Lye Chei; Melanie Sereny Brasher; Juan Zhang; Han-Zhu Qian; Chen Mao; David Bruce Matchar; Jie-Si Luo; Yi Zeng; Xiao-Ming Shi
Journal:  J Am Med Dir Assoc       Date:  2017-02-01       Impact factor: 4.669

7.  Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study.

Authors:  M F Elias; P A Wolf; R B D'Agostino; J Cobb; L R White
Journal:  Am J Epidemiol       Date:  1993-09-15       Impact factor: 4.897

8.  Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project.

Authors:  Chengxuan Qiu; Eva von Strauss; Bengt Winblad; Laura Fratiglioni
Journal:  Stroke       Date:  2004-07-01       Impact factor: 7.914

Review 9.  Dementia in the oldest old.

Authors:  Szófia S Bullain; María M Corrada
Journal:  Continuum (Minneap Minn)       Date:  2013-04

Review 10.  Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future.

Authors:  Timothy M Hughes; Kaycee M Sink
Journal:  Am J Hypertens       Date:  2015-11-11       Impact factor: 2.689

View more
  3 in total

Review 1.  High blood pressure in dementia: How low can we go?

Authors:  Yuda Turana; Jeslyn Tengkawan; Yook-Chin Chia; Boon Wee Teo; Jinho Shin; Guru Prasad Sogunuru; Arieska Ann Soenarta; Huynh Van Minh; Peera Buranakitjaroen; Chen-Huan Chen; Jennifer Nailes; Satoshi Hoshide; Sungha Park; Saulat Siddique; Jorge Sison; Apichard Sukonthasarn; Jam Chin Tay; Tzung-Dau Wang; Narsingh Verma; Yu-Qing Zhang; Ji-Guang Wang; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-12-09       Impact factor: 3.738

Review 2.  Neurodegenerative diseases and blood pressure variability: A comprehensive review from HOPE Asia.

Authors:  Yuda Turana; Robert Shen; Michael Nathaniel; Yook-Chin Chia; Yan Li; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-09       Impact factor: 2.885

Review 3.  The HOPE Asia Network activity for "zero" cardiovascular events in Asia: Overview 2020.

Authors:  Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-24       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.